Mechanisms of Atrial Pathoelectrophysiology in HCM (MAP HCM)

March 31, 2026 updated by: Guy's and St Thomas' NHS Foundation Trust

This study aims to learn why atrial fibrillation (AF), a type of irregular heartbeat, happens more often and is harder to treat in people with hypertrophic cardiomyopathy (HCM). HCM is an inherited condition where the heart muscle is thicker than usual.

Researchers will study electrical signals from the heart and advanced heart imaging. By doing this, they hope to better understand how AF behaves in people with HCM and why treatments may not work as well for them.

The information from this study may help improve future treatments for people who have both HCM and AF.

Study Overview

Status

Not yet recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

40

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients with hypertrophic cardiomyopathy and atrial fibrillation requiring atrial fibrillation ablation.

Description

Inclusion Criteria:

  • Paroxysmal or persistent atrial fibrillation
  • Diagnosis of hypertrophic cardiomyopathy
  • Patient planning to proceed to atrial fibrillation ablation following clinical consultation
  • Age 18-80 years
  • Able and willing to provide written informed consent
  • Able and willing to comply with study follow up requirements

Exclusion Criteria:

  • Any clinical contra-indication to ablation
  • Any disease limiting life expectancy to <1 year
  • Potential participant currently pregnant or breast feeding
  • Contraindication to MRI including renal dysfunction (eGFR<30ml/min)
  • Unable to understand verbal or written explanations given in English

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Patients with HCM and AF

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Changes in bipolar voltage, conduction velocity, refractory periods and conduction divergence of the atria in patients with HCM and AF compared to patients with AF and structurally normal hearts
Time Frame: At the time of the clinical ablation procedure
At the time of the clinical ablation procedure

Secondary Outcome Measures

Outcome Measure
Time Frame
Correlatation between the bipolar voltage in the atria with directly measured left atrial pressure, extent of late gadolinium enhancement and ventricular extracellular volume .
Time Frame: At the time of clinical ablation procedure
At the time of clinical ablation procedure
Reduction in AF inducibility in silico models following simulated ablation
Time Frame: Based on measurements taken during the clinical ablation procedure
Based on measurements taken during the clinical ablation procedure

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Guy's and St Thomas' NHS Foundation Trust

Collaborators

King's College London

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

March 8, 2026

Primary Completion (Estimated)

September 30, 2027

Study Completion (Estimated)

September 30, 2027

Study Registration Dates

First Submitted

March 2, 2026

First Submitted That Met QC Criteria

March 2, 2026

First Posted (Actual)

March 6, 2026

Study Record Updates

Last Update Posted (Actual)

April 6, 2026

Last Update Submitted That Met QC Criteria

March 31, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 339394

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Atrial Fibrillation (AF)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe